丙型肝炎持续病毒应答与肝硬化食管胃静脉曲张患者内镜治疗后再出血的相关性

肝脏 ›› 2021, Vol. 26 ›› Issue (6): 597-601.

丙型肝炎持续病毒应答与肝硬化食管胃静脉曲张患者内镜治疗后再出血的相关性

黄晓铨, 吴玲, 姜思雨, 李锋, 陈世耀

200032 上海复旦大学附属中山医院消化科

收稿日期:2021-01-29 出版日期:2021-06-30 发布日期:2021-07-19
通讯作者: 李锋,Email:li.feng2@zs-hospital.sh.cn
作者简介:共同第一作者:吴玲
基金资助:
中国肝炎防治基金会王宝恩肝纤维化研究基金(2019045)

The relationship between sustained virological response and re-bleeding risk of chronic hepatitis C patients after endoscopic management of gastroesophageal varices

HUANG Xiao-quan, WU Ling, JIANG Si-yu, LI Feng, CHEN Shi-yao

Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

Received:2021-01-29 Online:2021-06-30 Published:2021-07-19
Contact: LI Feng, Email: li.feng2@zs-hospital.sh.cn

摘要/Abstract

摘要： 目的探究丙型肝炎患者是否获得持续病毒应答(SVR)对内镜治疗食管胃静脉曲张破裂出血疗效的影响。方法纳入2013年1月至2019年12月复旦大学附属中山医院丙肝肝硬化食管胃静脉曲张破裂出血患者49例,根据其首次接受内镜下食管静脉曲张套扎联合胃组织胶治疗时HCV RNA是否阳性,分为SVR组和nSVR组,随访患者内镜治疗后再出血、肝硬化相关并发症及生存情况。结果 49例患者中,26例SVR组患者与23例nSVR组患者内镜治疗后1年、2年和3年的累积无出血率分别为78.4%比73.9%,58.9%比63.4%,58.9%比43.4%(P=0.478);两组患者内镜治疗后的3年累积生存差异无统计学意义(P=0.667)。食管套扎联合胃组织胶治疗是降低再出血的独立保护因素(HR 0.21,95% CI: 0.08~0.53, P=0.001)。结论丙肝患者是否获得SVR不影响内镜治疗食管胃静脉曲张破裂出血的疗效,内镜下食管静脉曲张套扎联合胃静脉曲张组织胶治疗是最佳选择。

关键词: 丙型肝炎, 持续病毒应答, 食管胃静脉曲张静脉曲张, 内镜治疗, 再出血

Abstract: Objective To investigate the impact of sustained virological response (SVR) on the re-bleeding risk of chronic hepatitis C patients after endoscopic management of gastroesophageal varices bleeding (GVB).Methods A total of 49 patients admitted to Zhongshan Hospital, Fudan University with HCV related GVB were included in this study. They were divided into SVR group (N=26 patients) and non-SVR group (N=23 patients) according to their serum HCV RNA levels detected at the time of primary endoscopic therapy for GVB by esophageal variceal ligation (EVL) combined with histoacryl injection (HI). The occurances of re-bleeding and other complications of cirrhosis, and the survival rates of these patients in three years after endoscopic treatment were follow-up.Results Kaplan-Meier survival analysis showed that there were no significant differences in the cumulative rebleeding-free rates at 1-year, 2-year and 3-year between the SVR group and the non-SVR group, the same went for the cumulative survival rates between these two groups. The results of Multivariate analysis showed that the clearance of HCV did not influence the efficacy of endoscopic management of HCV-related GVB. The endoscopic treatment of EVL plus HI is an independent protective factor against re-bleeding in HCV-related cirrhotic patients with GVB.Conclusion The clearance of HCV RNA did not influence the efficacy of endoscopic management of HCV-related GVB. EVL plus HI can be the optimal treatment selection in these patients.

Key words: Hepatitis C related cirrhosis, Sustained virological response, Gastroesophageal varices bleeding, Endoscopic treatment, Re-bleeding

黄晓铨, 吴玲, 姜思雨, 李锋, 陈世耀. 丙型肝炎持续病毒应答与肝硬化食管胃静脉曲张患者内镜治疗后再出血的相关性[J]. 肝脏, 2021, 26(6): 597-601.

HUANG Xiao-quan, WU Ling, JIANG Si-yu, LI Feng, CHEN Shi-yao. The relationship between sustained virological response and re-bleeding risk of chronic hepatitis C patients after endoscopic management of gastroesophageal varices[J]. Chinese Hepatolgy, 2021, 26(6): 597-601.

参考文献

[1] WHO Guidelines Approved by the Guidelines Review Committee, in guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. 2018, World Health Organization? World Health Organization 2018. Geneva.
[2] Persico M, Rosato V, Aglitti A, et al. Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis. Antivir Ther,2018.23:129-138.
[3] Mauro E, Crespo G, Montironi C, et al. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Hepatology,2018.67: 1683-1694.
[4] Gomez EV, Bertot LC, Rodriguez YS, et al. The natural history of HCV-related cirrhosis and its temporal progression across the different clinical stages. Hepatol Int,2014.8:527-39.
[5] Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology,2017.65:310-335.
[6] de Franchis, R. Expanding consensus in portal hypertension: report of the baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol,2015.63:743-52.
[7] Jacobson IM, Lim JK, Fried MW. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: care of patients who have achieved a sustained virologic response after antiviral therapy for chronic hepatitis C infection. Gastroenterology,2017.152:1578-1587.
[8] Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology,2010.51:2069-76.
[9] Krassenburg LAP, Maan R, Ramji A, et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol,2020.S0168-8278(20)33805-8.
[10] Nagaoki Y, Imamura M, Teraoka Y, et al. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. Hepatol Res,2020.50:1222-1233.
[11] Thabut D, Bureau C, Layese R, et al. Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy. Gastroenterology,2019.156:997-1009.
[12] Di Marco V, Calvaruso V, Ferraro D, et al. Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension. Gastroenterology,2016.151:130-139.
[13] Yuri Y, Nishikawa H, Enomoto H, et al. Impact of sustained virological response for gastroesophageal varices in hepatitis-C-virus-related liver cirrhosis. J Clin Med,2019.9:95.
[14] Tada T, Kumada T, Toyoda H, et al. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. J Gastroenterol Hepatol,2017.32:1982-1988.
[15] Kobayashi N, Iijima H, Tada T, et al. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Eur J Gastroenterol Hepatol,2018.30:546-551.
[16] Lens S, Rincón D, García-Retortillo M, et al. Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy. Clin Gastroenterol Hepatol,2015.13:1846-1853.